In a paper published today in Nature Genetics, Professor Julian Knight at the Wellcome Centre for Human Genetics and colleagues from the ULTRA-DD Consortium shows how genetics and knowledge of networks can prioritise drug targets for immune-mediated diseases.
The Priority Index or ‘Pi’ pipeline was developed by the study first-author Dr Hai Fang to be open-source and customisable, promoting collaborative efforts to accelerate early-stage drug development. This ethos was central to the ULTRA-DD Consortium, which included academic and pharma partners through an Innovative Medicines Initiative. A web interface allows users to visualise gene priority ratings, underlying data and analysis.
Read more (Wellcome Centre for Human Genetics website)